EYES Stock: The Big FDA News That Has Second Sight Shares Soaring investorplace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investorplace.com Daily Mail and Mail on Sunday newspapers.
Second Sight Medical Products Inc. plans to combine with Pixium Vision SA, a French company, to pursue their common quest to develop bionic vision systems.
The Sylmar company is working on its next-generation vision prosthetic, called the Orion system, which is complementary to a retinal-based system being made by Pixium.
According to Acting Chief Executive Matthew Pfeffer, both companies have been aware of each other for many years and have had interactions in the past. The transaction will secure the future of both companies by reducing overhead costs and creating synergies, he said.
Read the full story in the March 1 issue of the San Fernando Valley Business Journal.
Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market
Aims to create a global leader with potential to treat nearly all forms of blindness
Combined company to trade on Nasdaq and benefit from business and development synergies in the U.S. and Europe
Transaction provides broader access to financing sources to enable the combined company to accelerate the development and commercialization of its products
Pixium Vision to remain listed on Euronext Growth and to be the largest shareholder of the new combined company listed on Nasdaq
Transaction expected to close in late Q1 or the beginning of Q2 2021
Pixium Vision
Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market
Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market
Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market
Aims to create a global leader with potential to treat nearly all forms of blindness
Combined company to trade on Nasdaq and benefit from business and development synergies in the U.S. and Europe
Transaction provides broader access to financing sources to enable the combined company to accelerate the development and commercialization of its products